Wegovy vs. Ozempic: same semaglutide, different doses and uses

Same active ingredient, same maker, same once-weekly shot under the skin. The labels are where they part.

Ozempic (first approved 2017) is for adults with type 2 diabetes. It lowers blood sugar, reduces heart attack and stroke risk in people with diabetes and heart disease, and since January 2025 also slows kidney decline in people with diabetes and chronic kidney disease. Its ladder is 0.25 mg for four weeks, then 0.5 mg, 1 mg and 2 mg, with at least four weeks at each step.

Wegovy (2021) is for obesity, or overweight with a weight-related condition, in adults and in children aged 12 and older. It also covers heart-risk reduction in adults with heart disease and excess weight, and a fatty-liver condition called MASH with moderate to advanced fibrosis. The injection climbs 0.25, 0.5, 1 and 1.7 mg to a 2.4 mg maintenance dose. Wegovy HD, approved in March 2026, adds 7.2 mg for adults who have tolerated 2.4 mg for at least four weeks.

Both brands now have tablet versions too, at different doses and for the same split in uses.

No trial has put Wegovy against Ozempic. Each was tested for its own job, so the fair comparison is between their programs.

Ozempic's evidence is about blood sugar and organs. In SUSTAIN FORTE (Lancet Diabetes & Endocrinology, 2021), semaglutide 2 mg lowered HbA1c by 2.2 percentage points over 40 weeks, against 1.9 points on 1 mg. Weight fell 6.9 kg and 6.0 kg. In FLOW (NEJM, 2024), semaglutide 1 mg cut major kidney events by 24% versus placebo in 3,533 people with type 2 diabetes and kidney disease.

Wegovy's evidence is about weight and the heart. STEP 1 (NEJM, 2021) reported a mean weight change of −14.9% at 68 weeks on 2.4 mg, against −2.4% on placebo, in adults without diabetes. SELECT (NEJM, 2023) found 20% fewer cardiovascular deaths, heart attacks and strokes on 2.4 mg across 17,604 people with heart disease and overweight. STEP UP (Lancet Diabetes & Endocrinology, 2025) tested 7.2 mg: mean weight change was −18.7% at 72 weeks, versus −15.6% on 2.4 mg and −3.9% on placebo, counting everyone randomized. Novo Nordisk reports about 21% among people who stayed on treatment.

The practical point: weight-loss numbers quoted online usually come from Wegovy doses. Ozempic's ceiling is lower, and its trials measured blood sugar first.

The side effects match because the drug does. Stomach and bowel effects lead: nausea, diarrhea, vomiting and constipation, mostly in the weeks after a dose step.

Rates climb with dose. The Ozempic prescribing information lists nausea in 15.8% of people on 0.5 mg and 20.3% on 1 mg. The Wegovy prescribing information lists nausea in 44% on 2.4 mg, diarrhea in 30%, and vomiting and constipation in 24% each. At 7.2 mg, the Wegovy label adds a signal of its own: dysesthesia, meaning tingling, burning or skin sensitivity, in 22% of people, against 6% on 2.4 mg.

Less common but serious risks apply to both brands: pancreatitis, gallbladder disease, kidney injury from fluid loss, and worsening of existing diabetic eye disease. Low blood sugar is mainly a risk alongside insulin or a sulfonylurea, which is more typical on Ozempic. Each label carries a boxed warning about thyroid C-cell tumors seen in rodents, and neither drug is used with a personal or family history of medullary thyroid carcinoma or MEN 2.

Start with the diagnosis, because the label follows it.

Ozempic fits adults with type 2 diabetes who need better blood sugar control. It is the stronger match if you also have heart disease or chronic kidney disease, since it holds approvals for both.

Wegovy fits adults with obesity, or overweight plus a condition such as high blood pressure. It also fits teenagers 12 and older with obesity, adults with heart disease and excess weight, and adults with MASH liver fibrosis.

Wegovy HD fits a narrow group: adults already stable on 2.4 mg who need more effect. It is never a starting dose.

Neither fits if you have a personal or family history of medullary thyroid cancer or MEN 2. Severe gastroparesis is another reason both labels advise against use.

If weight is the only reason for treatment, asking for Ozempic is off-label, and insurers often deny it for that reason. Asking for Wegovy by name is usually the cleaner route. If cost rules out both brands, say so plainly. A prescriber can walk through options, including compounded semaglutide, which is not an FDA-approved product.